Brief: Kintor Pharma's Female Androgenetic Alopecia Drug met Main Goal Of Phase Ii Study In China
01/12/2022 11:43
Dec 1 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMA ANNOUNCED THE PRIMARY ENDPOINT OF PHASE II
CLINICAL STUDY FOR KX-826'S TREATMENT OF FEMALE ANDROGENETIC
ALOPECIA IN CHINA WAS MET
Source text for Eikon: ID:nPn1HF3wYa
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint